摘要
目的:评价赫赛汀和长春瑞滨联合化疗在治疗晚期乳腺癌中的疗效和不良反应。方法:将50例晚期乳腺癌患者分为两组。26例患者采用赫赛汀联合长春瑞滨方案治疗:赫赛汀静脉滴注,首次4mg/kg,其后每周1次,2mg/kg,连续使用;长春瑞滨25mg/m2静脉滴注,d1,8;每3周为1周期。24例患者采用长春瑞滨和顺铂方案(NP方案)治疗:长春瑞滨40mg/天,d1,8;顺铂25mg/m2,d1,3,每3周为1周期。结果:赫赛汀联合长春瑞滨方案有效率为65.4%,NP方案有效率为54.2%,(P<0.05)。结论:赫赛汀联合长春瑞滨治疗晚期乳腺癌是有效且安全的治疗方案,不良反应可耐受,可作为晚期乳腺癌一线方案应用。
Objective：To evaluate the efficacy and toxicity of Herceptin combined with vinorelbine in treatment of advanced breast cancer. Methods： Fifty cases of advanced breast cancer were divided into 2 groups：26 cases were treated with Herceptin and vinorelbine ： Herceptin was used by the way of intravenous drip at the first time with a dose of 4mg/kg, then, continuous to use the dose of 2mg/kg , one week one time;Vinorelbine was used by the way of intravenous drip at the first day and at the 8th day with a dose of 25mg/m2 ,3 weeks for a cycle ;24 cases were treated with NP method： NVB was used the first day and the 8th day with a dose of 40mg/day ,DDP was used at the first day and the 3th day with a dose of 25mg/m2, 3 weeks for a cycle. Results： The efficiency of Herceptin and vinorelbine method was 65.4%, and the NP method was 54.2%. The efficacy was significantly different between the 2 groups. Conclusion： Herceptin combined with vinorelbine in treatment of advanced breast cancer is effective and safe, and there was significant difference between the two groups, it can he applied for the first line chemotherapy.
出处
《现代肿瘤医学》
CAS
2011年第2期276-278,共3页
Journal of Modern Oncology
关键词
赫赛汀
长春瑞滨
顺铂
乳腺癌
联合治疗
Herceptin
vinorelbine
cisplatin
breast cancer
combination therapy
作者简介
杜珂（1979-），女，湖北襄阳人，本科，住院医师，主要从事肿瘤内科研究。
